Medtronic upgraded to Outperform at Credit Suisse
Credit Suisse upgraded Medtronic Inc (NYSE: MDT) from “neutral” to “outperform.” Credit Suisse also added MDT to its Focus List and raised the target price for MDT from $41 to $49. According to Credit Suisse, the base business of MDT was stabilizing and the risk/reward profile of MDT stocks was compelling.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
